Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

179
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

307
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
307
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

210
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
210
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

359
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
359
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

203
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
203

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Steatotic liver disease in Latin America: current views and perspectives.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis-By Addressing One Issue Do We Create Another? Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Editorial: Pushing Forward With Pharmacotherapies for Patients With Alcohol-Associated Cirrhosis-Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Implementation of Mobile-Based Programs for Alcohol Cessation in the Treatment of Alcohol-associated Liver Disease: Protocol for a Type 1 Hybrid Implementation-Effectiveness Trial.

JMIR research protocols·2026
Same author

Serum HMGB1 and Alcohol-Related Liver Disease.

Journal of clinical medicine·2026
Same author

Letter: Unmasking the Risks-The Need for Robust Data on Baclofen in Cirrhotic Patients. Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026
See all related articles

Related Experiment Video

Updated: Jan 13, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

1.4K

Integrated Alcohol Use Disorder and Liver Disease Management.

Hanna Blaney1, Adelina Horhat2, Abdulmalik Saleem3

  • 1Medstar Transplant Hepatology Institute, MedStar Georgetown University Hospital, Washington, District of Columbia.

Seminars in Liver Disease
|October 28, 2025
PubMed
Summary
This summary is machine-generated.

Integrated care for alcohol-associated liver disease (ALD) and alcohol use disorder (AUD) improves patient outcomes. This multidisciplinary approach is feasible and effective for managing these dual conditions.

More Related Videos

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.5K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K

Related Experiment Videos

Last Updated: Jan 13, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

1.4K
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.5K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K

Area of Science:

  • Hepatology
  • Addiction Medicine
  • Public Health

Background:

  • Alcohol-associated liver disease (ALD) is a major global health issue linked to hazardous alcohol consumption.
  • Alcohol use disorder (AUD) frequently co-occurs with ALD, complicating patient management.
  • Current treatment rates for AUD in ALD patients remain low, highlighting a significant care gap.

Purpose of the Study:

  • To review the epidemiology, diagnosis, and treatment of AUD and ALD.
  • To examine successful integrated care models for co-occurring AUD and ALD.
  • To identify knowledge gaps and future research directions in managing these conditions.

Main Methods:

  • Literature review of AUD and ALD epidemiology, diagnosis, and treatment.
  • Analysis of integrated care models involving hepatologists and AUD specialists.
  • Discussion of research needs, including peri-transplantation care and harm reduction.

Main Results:

  • Integrated care models show promise in reducing alcohol relapse, healthcare utilization, and improving mortality.
  • Multidisciplinary care is essential for addressing the dual pathologies of AUD and ALD.
  • Successful integrated care demonstrates feasibility and effectiveness.

Conclusions:

  • Integrated care for AUD and ALD is effective and feasible.
  • Addressing AUD is crucial for comprehensive ALD management.
  • Future research should focus on expanding integrated care, harm reduction, and peri-transplantation support.